Lantern Pharma Expands LP-300 Clinical Trial for Non-Smoking Lung Cancer Patients to Japan and Taiwan

Lantern Pharma Inc. has expanded its Harmonic™ trial for LP-300, a Phase 2 clinical study targeting non-small cell lung cancer (NSCLC) in never-smokers, to include Japan and Taiwan. This move is expected to expedite data collection for LP-300's evaluation and development as a therapy for relapsed and inoperable primary adenocarcinoma of the lung when combined with chemotherapy. Additionally, it aims to provide a crucial treatment option for never-smoking lung cancer patients in Japan and Taiwan, where one-third of all lung cancer diagnoses occur among individuals who have never smoked. Dr. Yashushi Goto, a physician and researcher at the National Cancer Center of Japan, will lead the trial in Japan, recognizing the potential of LP-300 to address the unmet needs of never-smoking NSCLC patients, particularly those harboring driver mutations like EGFR, ALK, ROS1, and MET. The Harmonic™ trial, designed to assess the effect of LP-300 in combination with standard-of-care chemotherapy, holds promise for transforming the treatment landscape for this patient population globally.